📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Ajooni Biotech Secures Record ₹47.52 Cr Order; Triples Capacity to 1.8 Lakh MT
Ajooni Biotech has secured its largest-ever single order worth ₹47.52 crores for cattle feed from an existing customer, representing a significant portion of its current revenue. The company also announced the commissioning of its new Khanna plant, which increases total annual production capacity from 60,000 MT to 180,000 MT. For 9M FY26, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Furthermore, the board is evaluating a potential merger with Healthy Biosciences Limited to drive inorganic growth.
Key Highlights
Received record-breaking order worth ₹47.52 crores for scientifically formulated cattle feed
Commissioned new facility in Khanna, Punjab, tripling total annual capacity to 1,80,000 MT
Reported 9M FY26 financial performance with ₹122.87 crore revenue and ₹3.37 crore PAT
Board is actively discussing the merger/amalgamation of Healthy Biosciences Limited with Ajooni
New plant technology expected to significantly reduce production costs and improve margins
💼 Action for Investors
Investors should view the massive capacity expansion and record order book as strong growth catalysts for FY27. Monitor the progress of the proposed merger with Healthy Biosciences for potential synergy benefits.
Ajooni Biotech Bags Record ₹47.52 Cr Order; Total Capacity Reaches 1.8 Lakh MT
Ajooni Biotech has secured its largest-ever order valued at ₹47.52 crores from an existing client for cattle feed supply. This milestone coincides with the commissioning of a new plant in Khanna, Punjab, which triples the company's total annual production capacity to 1,80,000 MT. For the 9M FY26 period, the company reported a revenue of ₹122.87 crores and a PAT of ₹3.37 crores. Additionally, the board is exploring a strategic merger with Healthy Biosciences Limited to further consolidate its market presence.
Key Highlights
Secured the biggest-ever order in company history worth ₹47.52 crores.
Commissioned a new 1,20,000 MT plant, taking total capacity to 1,80,000 MT per year.
Reported 9M FY26 total revenue of ₹122.87 crores and PAT of ₹3.37 crores.
Board is currently evaluating a merger proposal with Healthy Biosciences Limited.
💼 Action for Investors
Investors should monitor the company's ability to maintain margins with the new capacity and track the progress of the proposed merger. The significant order book provides strong revenue visibility for the upcoming quarters.
Ajooni Biotech Secures Major Cattle Feed Order Worth Rs. 47.52 Crores
Ajooni Biotech Limited has successfully secured a significant order valued at Rs. 47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the company's strengthening market position in the animal nutrition segment. The contract underscores growing demand and customer confidence in the company's product quality. This development is expected to provide a substantial boost to the company's revenue and operational scale in the near term.
Key Highlights
Received a new supply order worth Rs. 47.52 crores.
Order pertains to the supply of scientifically formulated cattle feed.
Strengthens the company's footprint in the animal nutrition industry.
Reflects robust demand and customer trust in product excellence.
💼 Action for Investors
Investors should view this as a positive growth indicator and monitor the company's ability to execute this order efficiently. Watch for the impact on upcoming quarterly revenue and profit margins.
Ajooni Biotech Secures Significant Order Worth ₹47.52 Crores for Cattle Feed
Ajooni Biotech Limited has announced the receipt of a substantial order valued at ₹47.52 crores for the supply of its scientifically formulated cattle feed. This order from a valued customer highlights the growing demand for the company's animal nutrition products and strengthens its market position. The contract represents a significant milestone in the company's growth journey and reflects strong customer confidence in its product quality. This development is expected to contribute positively to the company's revenue and operational scale.
Key Highlights
Secured a major order worth ₹47.52 crores for cattle feed supply
Reinforces the company's presence in the specialized animal nutrition segment
Demonstrates strong customer trust and demand for scientifically formulated products
Significant milestone expected to drive future revenue growth
💼 Action for Investors
Investors should view this as a positive growth indicator for the company's top-line and monitor the execution timeline of this order. The stock may see positive momentum given the substantial size of the order relative to the company's typical operations.
Ajooni Biotech Q3 Net Profit Jumps 125% YoY to ₹1.65 Cr; Merger Proposal Deferred
Ajooni Biotech reported a strong financial performance for the quarter ended December 31, 2025, with revenue from operations growing 72.6% YoY to ₹58.75 crore. Net profit for the quarter surged by 125.7% YoY to ₹1.65 crore, up from ₹0.73 crore in the same period last year. For the nine-month period, the company has already matched its previous full-year profit, reaching ₹3.37 crore. While the board discussed a merger with Healthy Biosciences Limited, the decision has been deferred for further evaluation, which remains a key watchpoint for future growth.
Key Highlights
Revenue from operations grew 72.6% YoY to ₹5,875.33 Lakhs in Q3 FY26.
Net profit for the quarter increased 125.7% YoY to ₹164.80 Lakhs.
9-month (Apr-Dec 2025) revenue reached ₹12,175.61 Lakhs vs ₹8,541.75 Lakhs YoY.
Earnings Per Share (EPS) for the quarter improved to ₹0.10 from ₹0.04 YoY.
Board deferred the merger proposal of Healthy Biosciences Limited pending further internal evaluation.
💼 Action for Investors
Investors should take note of the significant top-line and bottom-line expansion; however, they should monitor updates regarding the deferred merger which could impact long-term valuation.
Ajooni Biotech Commences Production & Receives Orders Worth ₹27 Crores
Ajooni Biotech Limited has announced the commencement of commercial production at its newly installed manufacturing facilities in Khanna, Punjab. This expansion is expected to significantly contribute to the company's revenue and market presence. Furthermore, the company has secured new orders for cattle feed valued at ₹27 Crores, demonstrating strong customer trust in both domestic and export markets. Investors should monitor the impact of this increased production capacity and order fulfillment on the company's future financial performance.
Key Highlights
Commercial production commenced at newly installed manufacturing facilities.
Received new orders for cattle feed valued at ₹27 Crores.
New facility located in Khanna, Punjab.
💼 Action for Investors
Investors should closely monitor Ajooni Biotech's revenue growth and profitability in upcoming quarters to assess the impact of the new production facility and order book. Review the company's quarterly reports for updates on capacity utilization and order execution.